GC Biopharma Statistics

Total Valuation

GC Biopharma has a market cap or net worth of KRW 1.52 trillion. The enterprise value is 2.60 trillion.

Market Cap	1.52T
Enterprise Value	2.60T

Important Dates

The last earnings date was Friday, February 14, 2025.

Earnings Date	Feb 14, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

GC Biopharma has 11.41 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	11.41M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.95%
Owned by Institutions (%)	17.93%
Float	5.45M

Valuation Ratios

PE Ratio	n/a
Forward PE	40.56
PS Ratio	0.93
PB Ratio	1.18
P/TBV Ratio	1.58
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 22.74, with an EV/FCF ratio of -45.55.

EV / Earnings	-137.99
EV / Sales	1.58
EV / EBITDA	22.74
EV / EBIT	75.36
EV / FCF	-45.55

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.59.

Current Ratio	1.55
Quick Ratio	0.66
Debt / Equity	0.59
Debt / EBITDA	7.89
Debt / FCF	-15.63
Interest Coverage	0.86

Financial Efficiency

Return on equity (ROE) is -1.47% and return on invested capital (ROIC) is 0.88%.

Return on Equity (ROE)	-1.47%
Return on Assets (ROA)	0.76%
Return on Invested Capital (ROIC)	0.88%
Return on Capital Employed (ROCE)	1.66%
Revenue Per Employee	818.31M
Profits Per Employee	-9.39M
Employee Count	2,009
Asset Turnover	0.60
Inventory Turnover	1.99

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +11.64% in the last 52 weeks. The beta is 0.97, so GC Biopharma's price volatility has been similar to the market average.

Beta (5Y)	0.97
52-Week Price Change	+11.64%
50-Day Moving Average	152,556.00
200-Day Moving Average	141,882.00
Relative Strength Index (RSI)	37.46
Average Volume (20 Days)	50,043

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GC Biopharma had revenue of KRW 1.64 trillion and -18.85 billion in losses. Loss per share was -1,652.01.

Revenue	1.64T
Gross Profit	462.54B
Operating Income	33.28B
Pretax Income	-26.08B
Net Income	-18.85B
EBITDA	113.18B
EBIT	33.28B
Loss Per Share	-1,652.01

Full Income Statement

Balance Sheet

The company has 46.67 billion in cash and 892.78 billion in debt, giving a net cash position of -846.11 billion or -74,134.63 per share.

Cash & Cash Equivalents	46.67B
Total Debt	892.78B
Net Cash	-846.11B
Net Cash Per Share	-74,134.63
Equity (Book Value)	1.52T
Book Value Per Share	112,965.13
Working Capital	432.09B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.54 billion and capital expenditures -55.58 billion, giving a free cash flow of -57.12 billion.

Operating Cash Flow	-1.54B
Capital Expenditures	-55.58B
Free Cash Flow	-57.12B
FCF Per Share	-5,004.79

Full Cash Flow Statement

Margins

Gross margin is 28.14%, with operating and profit margins of 2.02% and -1.15%.

Gross Margin	28.14%
Operating Margin	2.02%
Pretax Margin	-1.59%
Profit Margin	-1.15%
EBITDA Margin	6.88%
EBIT Margin	2.02%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 1,500.00, which amounts to a dividend yield of 1.13%.

Dividend Per Share	1,500.00
Dividend Yield	1.13%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	1.13%
Earnings Yield	-1.24%
FCF Yield	-3.75%

Dividend Details

Stock Splits

The last stock split was on June 7, 2013. It was a forward split with a ratio of 1.05.

Last Split Date	Jun 7, 2013
Split Type	Forward
Split Ratio	1.05

Scores

GC Biopharma has an Altman Z-Score of 1.9. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.9
Piotroski F-Score	n/a